Legalize59765 laws
59765 laws
- § 360bbb–3c. Expedited development and review of medical products for emergency uses
- § 360bbb–4. Countermeasure development, review, and technical assistance
- § 360bbb–4a. Priority review to encourage treatments for agents that present national security threats
- § 360bbb–4b. Medical countermeasure master files
- § 360bbb–5. Critical Path Public-Private Partnerships
- § 360bbb–5a. Emerging technology program
- § 360bbb–6. Risk communication
- § 360bbb–7. Notification
- § 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- § 360bbb–8a. Optimizing global clinical trials
- § 360bbb–8b. Use of clinical investigation data from outside the United States
- § 360bbb–8c. Patient participation in medical product discussion
- § 360bbb–8d. Notification, nondistribution, and recall of controlled substances
- § 360b–1. Priority zoonotic animal drugs
- § 360e–1. Pediatric uses of devices
- § 360c. Classification of devices intended for human use
- § 360cc. Protection for drugs for rare diseases or conditions
- § 360ccc. Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs
- § 360ccc–1. Index of legally marketed unapproved new animal drugs for minor species
- § 360ccc–2. Designated new animal drugs for minor use or minor species
- § 360c–1. Reporting
- § 360d. Performance standards
- § 360dd. Open protocols for investigations of drugs for rare diseases or conditions
- § 360ddd. Definitions
- § 360ddd–1. Regulation of medical gases
- § 360ddd–2. Inapplicability of drug fees to designated medical gases
- § 360e. Premarket approval
- § 360ee. Grants and contracts for development of drugs for rare diseases and conditions
- § 360eee. Definitions
- § 360eee–1. Requirements
- § 360eee–2. National standards for prescription drug wholesale distributors
- § 360eee–3. National standards for third-party logistics providers
- § 360eee–4. Uniform national policy
- § 360ee–1. FDA rare neurodegenerative disease grant program
- § 885. Burden of proof; liabilities
- § 360e–3. Breakthrough devices
- § 360e–4. Predetermined change control plans for devices
- § 360f. Banned devices
- § 360ff. Priority review to encourage treatments for rare pediatric diseases
- § 360fff. Definitions
- § 360fff–1. Submission of requests
- § 360fff–2. Eligibility determinations; data submission; filing
- § 360fff–3. GRASE determination
- § 360fff–4. Guidance; other provisions
- § 360fff–5. Repealed. [Pub. L. 116–136, div. A, title III, § 3854(b)(5)](/us/pl/116/136/dA/tIII/s3854/b/5), Mar. 27, 2020, [134 Stat. 456](/us/stat/134/456)
- § 360fff–6. Non-sunscreen time and extent applications
- § 360fff–8. Sunset
- § 360ff–1. Targeted drugs for rare diseases
- § 360g. Judicial review
- § 2652c. Assistant Secretary of State for Verification and Compliance